^
Association details:
Biomarker:GNA11 mutation
Cancer:Melanoma
Drug:Zolinza (vorinostat) (HDAC inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Vorinostat in Treating Patients With Metastatic Melanoma of the Eye

Excerpt:
Tumor GANQ, GNA11, and BAP1 mutational status must be determined on all patients; if initial testing is performed locally or not available, MSKCC or Columbia University Medical Center (CUMC) patients must consent to provide a tumor block or unstained slides to MSKCC or CUMC for central review of mutational status; if tissue is not available, a pre-treatment biopsy will be necessary for eligibility.
Trial ID: